GS
KRYS icon

GTS Securities’s Krystal Biotech KRYS Stock Holding History

GTS Securities’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,200
Closed -$391K – 4136
2024
Q1 		$391K Buy
+2,200
New +$306K ﹤0.01% 2780

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GTS Securities's KRYS Position: Q1 2026 in Review

GTS Securities opened a new position in Krystal Biotech (KRYS) in Q1 2026: 1,108 shares worth $286K. The stake represents 0.01% of the portfolio and ranks #1133 among its holdings.

367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • GTS Securities held 1,108 shares of Krystal Biotech worth $286K as of Q1 2026.
  • Krystal Biotech was a new GTS Securities position in Q1 2026.
  • Krystal Biotech made up 0.01% of GTS Securities's portfolio in Q1 2026, its #1133 holding.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on GTS Securities's 13F filing for Q1 2026, filed 15 May 2026.